Alpha Cognition Inc. filings document the regulatory record of a British Columbia biopharmaceutical issuer with no-par-value common shares listed on Nasdaq under ACOG. The disclosures identify the company as an emerging growth company and cover formal reporting around ZUNVEYL commercialization, financial results, operational updates, and capital and compensation arrangements.
Recent Form 8-K filings address results of operations, Regulation FD disclosures, board appointments and departures, equity awards under incentive plans, and material agreements tied to legacy Memogain asset and license obligations. Proxy materials describe annual general meeting matters, including director elections, board size, auditor appointment, shareholder voting procedures, and accompanying annual financial statement materials.
Alpha Cognition Inc. shareholder Ikarian Capital, LLC reported beneficial ownership of 1,056,259 common shares, equal to 4.9% of Alpha Cognition’s outstanding stock. The stake is held through Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts.
The 4.9% figure is based on 21,742,104 common shares outstanding as of November 13, 2025. The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Alpha Cognition.
Alpha Cognition Inc. received a new Schedule 13G reporting a 5.1% passive stake in its common shares. Manchester Management Company, LLC and Manchester Management PR, LLC each report beneficial ownership of 1,127,181 common shares, representing 5.1% of the class as of 12/30/2025.
The firms report shared voting and dispositive power over all 1,127,181 shares and no sole power. All securities are directly owned by advisory clients of Manchester Management PR, LLC, and no individual client is deemed to own more than 5% of the class. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Alpha Cognition.
Investment Company, Inc., a Delaware investment adviser, reports beneficial ownership of 2,172,036 Alpha Cognition Inc. common shares and pre-funded warrants, representing 9.9% of the class as of 12/31/2025. It has sole voting and dispositive power over these securities through several affiliated funds.
The position is held for ordinary course investment purposes and is not aimed at changing or influencing control of Alpha Cognition. The pre-funded warrants may only be exercised to the extent total beneficial ownership does not exceed 9.99% of Alpha Cognition’s outstanding common shares.
Alpha Cognition Inc. received a Schedule 13G reporting a significant shareholder position by Opaleye-related entities. Opaleye Management Inc., Opaleye, L.P., and James Silverman report beneficial ownership of 2,070,784 shares of Alpha Cognition common stock, representing 9.52% of the class as of 12/31/2025.
Most of the position, 2,015,784 shares or 9.27% of the class, is held by Opaleye, L.P. The filer reports shared voting and shared dispositive power over 2,070,784 shares and no sole power. The reporting persons certify the holdings are not for the purpose of changing or influencing control of the company.
Alpha Cognition Inc. director Phillip Joseph Mertz reported new equity awards dated January 14, 2026. He received 7,241 common shares at a price of $0, described as restricted stock units that vest one year from the grant date. He was also granted 8,437 common share options with an exercise price of $6.56, which will vest one year from grant and expire on January 14, 2036.
Following these awards, Mertz directly holds 29,703 common shares and 8,437 options. An additional 12,560 common shares are held indirectly by Mertz Holdings, and he disclaims beneficial ownership of those securities except to the extent of his pecuniary interest.
Alpha Cognition Inc. director Robert James Wills reported equity awards received on 01/14/2026. He was granted 7,241 common shares as restricted stock units at a price of $0, increasing his directly held common shares to 22,241. He also received 8,437 common share options with an exercise price of $6.56 per share and a reported value of $0 at grant, leaving him with 8,437 options held directly.
The filing notes that the restricted stock units vest one year from the grant date, and the options will vest one year from the grant date, with the options expiring on 01/14/2036.
Alpha Cognition Inc. director Leonard Powell Mertz reported new equity awards. On 01/14/2026, he acquired 7,241 common shares as restricted stock units at $0, which will vest one year from the grant date. On the same date, he was granted 8,437 common share options with an exercise price of $6.56; these options also vest one year from the grant date and expire on 01/14/2036.
After these awards, he directly beneficially owned 145,736 common shares and 8,437 common share options. He also indirectly beneficially owned 121,503 common shares through The Len Mertz Trust.
Alpha Cognition Inc. director Kenneth Anthony Cawkell reported new equity awards in the form of common shares and stock options. On January 14, 2026, he received 7,241 common shares at a price of $0, described as restricted stock units that vest one year from the grant date. Following this grant, he directly held 107,740 common shares.
On the same date, he was also granted 8,437 common share options with an exercise price of $6.56 per share, which will vest one year from the grant date and expire on January 14, 2036. The filing also notes indirect holdings of 50,000 common shares through Cawbro Holdings Ltd. and 67,977 common shares through CMI Cornerstone Management Corp., and states that he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Alpha Cognition Inc. director Rajeev Kumar Bakshi reported new equity awards. On 01/14/2026 he received 7,241 restricted stock units of common shares at no purchase price, which vest one year from the grant date. He was also granted 8,437 common share options with a conversion or exercise price of $6.56 per share; these options also vest one year from the grant date.
After these awards, he beneficially owns 12,283 common shares directly and 6,801 common shares indirectly through Vincorp Holdings Ltd., plus 8,437 stock options that can be exercised into common shares once vested.
Alpha Cognition Inc. reported that its Compensation Committee granted new equity awards to senior executives under the 2025 Stock and Incentive Plan on January 9, 2026. These long-term incentives are structured as a mix of restricted stock units (RSUs), stock options, and, for the CEO, performance-based share units.
Chief Executive Officer Michael McFadden received 190,549 RSUs vesting in three equal annual installments from January 9, 2027 to January 9, 2029, 177,576 stock options vesting one-third on January 9, 2027 and quarterly thereafter, and 76,220 performance share units that can vest over two years if the share price reaches levels from $12.00 up to $28.00 for specified trading periods. Chief Operating Officer Lauren D’Angelo received 137,195 RSUs and 106,545 stock options with similar time-based vesting, while Interim Chief Financial Officer Henry Du received 20,579 RSUs and 15,982 stock options on the same vesting schedule.